Munich, Germany

Marian Zajac

This inventor holds 1 USPTO granted patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marian Zajac. Retrieved from https://idiyas.com/inventor/marian-zajac

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Marian Zajac: Innovator in Pharmaceutical Chemistry

Introduction

Marian Zajac is a notable inventor based in Munich, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative processes and compounds.

Latest Patents

Marian Zajac holds a patent for the compound (3,4-dichloro-phenyl)-((S)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride. This invention focuses on a novel process for the preparation of this compound and its hydrates, which are recognized as pharmaceutically active substances.

Career Highlights

Zajac is currently associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work has contributed to advancements in drug development and manufacturing processes.

Collaborations

Throughout his career, Marian Zajac has collaborated with esteemed colleagues such as Jean-Michel Adam and Charles Alois Dvorak. These partnerships have fostered innovation and enhanced the impact of their collective research.

Conclusion

Marian Zajac's contributions to pharmaceutical chemistry and his innovative patent demonstrate his commitment to advancing healthcare solutions. His work continues to influence the industry and improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…